Harvard Bioscience shares surge 15.73% after-hours after announcing $4M annual savings from manufacturing consolidation.

Harvard Bioscience surged 15.73% in after-hours trading following its announcement of a strategic consolidation of manufacturing operations. The company will close its Holliston, MA facility and shift U.S. production to its Minneapolis, MN hub, while relocating certain operations to Germany, Sweden, and the UK. The move aims to streamline operations, reduce costs, and enhance efficiency, with projected savings of $3 million in 2027 and $4 million annually thereafter. CEO John Duke emphasized the initiative’s role in simplifying the manufacturing footprint, leveraging global expertise, and accelerating long-term value creation. The phased transition, expected to conclude by Q1 2027, is designed to avoid disruptions while generating operational synergies. Investors appeared to view the cost-cutting and efficiency-enhancing measures as a positive step toward stabilizing the company’s financial position and improving profitability.